572 



SUBJECT INDEX 



Vitamin B (continued) 



concentration of, 26-48, 55-70, 77 360, 

 377, 406, 447, 452, 468, 474, 481, 

 496 



conditions for testing antineuntic ac- 

 tion of, 39, 40, 100. See also de- 

 termination; measurement 



crystalline salts of, 38, 39, 43, 44, 60 



day-dose of, 67 



deficiency, 14-16, 20, 24-26, 50-57 70- 

 85 95 96, 100-105, 366, 368, 376, 

 381, 391, 393, 394, 425, 440, 446, 

 448 457-459, 471, 477, 479, 483, 

 484, 488, 490 ^ ^^ 



determination, 37, 39, 45, 48, 67, 85, 

 95-105, 353, 357, 370, 371, 386, 

 387, 392, 455, 456, 498 



destruction of, 106-108, 394, 406, 452, 

 469 



development of knowledge of, 24-/0 



distribution of, 85-95, 356, 377, 395, 

 473 



effect of nitrous acid on, 107, 108 

 of other agents, see stability 



extractability of, 108. See also con- 

 centration of 



factors of, 22, 23, 45, 56, 57, 62, 63, 

 68, 69, 95, 102, 110, 111-126, 129- 



131, 147 . . J 



feeding method for quantitative de- 

 termination of, 99-105, 353, 370, 



386, 387, 392, 455, 456, 498, 508 

 fractionation. See concentration, and 



factors 



gold compound of, 44, 67, 68 



growth-promoting function, 50-70. See 

 also factors, and the general 

 description of vitamin B 



impure lactose as source of, 52, 53 



in body, 85-95, 377, 395, 473, 474, 

 508 



in foods, 85-95, 377, 473, 474 



in infant feeding, 380, 386. See also 

 relations to nutrition 



in insulin treatment, 381 



inactivation of, 46, 106-108, 394, 406, 

 452, 469, 472. See also chemical 

 nature, and the general descrip- 

 tion of vitamin B 



injection of, 74 



injection method for determination, 

 105 



instability of, as possibly related to 

 isomeric changes, 34-37 



Jendrassik reaction for, 447 



measurement of activity, potency, or 

 value, 37, 39, 45 63, 65-66, 85- 

 95, 95-105, 353, 357, 370, 386, 



387, 392, 455, 456, 498, 508 

 metallic double salts of, 37, 38, 43, 



44, 62, 67, 68 

 nomenclature, 20-23, 384, 446 



Vitamin B (continued) 



Osborne- Wakeman concentrate of, 

 from yeast, 57-58 



oxidation of, 107, 108 



parallelism between lack of, and sim- 

 ple starvation, 70-79 



paralysis in rats upon diets deficient 

 in, 104, 105 



partial deficiency, 70. See also defi- 

 ciency 



parenteral administration of, 74, 105, 

 375 



physiological properties and signifi- 

 cance of, 70-85, 440, 485 



picrate. See concentration of 



picrolonate of, 43, 66-69 



precipitation of, with chloroplatinic 

 acid, 46 

 with gold chloride, 67-68 



preparation of concentrates of, 47, 48, 

 55-70, 77, 360, 377, 447, 452, 468, 

 474, 481, 496 

 of proteins free from, 474 



presence in animal organs and tissues, 

 55, 75, 76, 85-95, 377, 395, 473, 

 474 



properties of, 24-85, 104-110, 394, 406, 

 452, 469, 472 



protective vs. curative tests, 37. See 

 also determination 



quantitative determination, 95-105 



rate of destruction upon heating, 106 



relation to appetite, 54, 71-73, 376 

 to gastric motility, 376 

 to infection, 393, 488 

 to metabolism, 54, 75-82, 373, 382, 



383, 384, 412, 462, 485 

 to muscular work, 377 

 to nutrition, 52, 70-85, 364, 373, 376, 

 380, 382, 383, 386, 392, 407, 412, 

 430, 437, 458, 462, 463, 474, 479, 

 480 

 to renal enlargement on high pro- 

 tein diet, 395 

 to secretion, 73, 74, 375, 376, 381, 

 436 



silver complex of, 37, 38 



solubility, 56, 57, 69, 108. See also 

 general description of vitamin B 



sources of, in experimental diets, 73, 

 100, 102, 131-133 



sparing action of fat, 392 



stable silver compound of, 36, 37 



stability of, 46, 58, 59, 105-108, 394, 

 406, 452, 469, 472 



standardized animals for determina- 

 tion of, 101, 102, 103, 105 



subcutaneous injection of, 66, 74, 105, 

 375 



successive adsorptions of, 66 



suitability of rats as test animals for, 

 104 



